Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.645 USD | -2.40% | -7.84% | -21.28% |
May. 02 | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
May. 01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.28% | 263M | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating